{"paper_id":"3e56ef66-6753-4d3e-8716-303d72e58d9b","body_text":"Abstract\nTargeted drug therapies offer a promising approach for treating complex diseases, with combinational drug therapies often employed to enhance therapeutic efficacy. However, unintended drug-drug interactions may undermine treatment outcomes or cause adverse side effects. In this work, we propose a novel joint learning framework for the simultaneous prediction of effective drug combinations and drug-drug interactions, based on coupled tensor-tensor factorization. Specifically, we model drug combination therapies and DDI by representing drug-drug-disease associations and drug-drug interaction profiles as coupled three-way tensors. To address the challenges of data incompleteness and sparsity, the proposed model integrates auxiliary drug similarity information, such as chemical structure similarities, drug-specific side effects, drug target profiles, and drug inhibition data on cancer cell lines, within a multi-view learning frame-work. For optimization, we adopt a modified Alternating Direction Method of Multipliers (ADMM) algorithm that ensures convergence while enforcing non-negativity constraints. In addition to standard tensor completion tasks, we further evaluate the proposed method under a more realistic new-drug prediction setting, where all interactions involving a previously unseen drug are withheld. This scenario closely aligns with real-world applications, in which reliable predictions for emerging or under-studied compounds are essential. We evaluate the proposed method on a comprehensive dataset compiled from multiple sources, including DrugBank, CDCDB, SIDER, and PubChem. Our experiments show that SI-ADMM maintains robust performance and achieves the best results comparing to other tensor factorization approaches, with or without auxiliary information, particularly in the new-drug prediction setting. The implementation of our method is publicly available at: https://github.com/Xiaoge-Zhang/SI-ADMM.\nCompeting Interest Statement\nThe authors have declared no competing interest.\nFootnotes\nEmails: xxz705{at}case.edu, zxf177{at}case.edu, kxt439{at}case.edu, hxc501{at}case.edu, jxl175{at}case.edu\nAddition of Acknowledgment Section. Funding information is added to the manuscript. All other sections remain unchanged.","source_license":"CC-BY-4.0","license_restricted":false}